Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.
about
Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunitySerum toll-like receptors are potential biomarkers of radiation pneumonia in locally advanced NSCLC.Tumor suppressor activity of RIG-I.Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia.Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy.Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.
P2860
Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.
@en
type
label
Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.
@en
prefLabel
Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.
@en
P2093
P2860
P1476
Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.
@en
P2093
Masahiro Azuma
Misako Matsumoto
Tsukasa Seya
P2860
P304
P356
10.1517/14728222.2013.765407
P407
P577
2013-02-18T00:00:00Z